In last trading session, Seres Therapeutics Inc (NASDAQ:MCRB) saw 2.39 million shares changing hands with its beta currently measuring 2.26. Company’s recent per share price level of $0.83 trading at $0.02 or 3.09% at ring of the bell on the day assigns it a market valuation of $125.53M. That closing price of MCRB’s stock is at a discount of -727.71% from its 52-week high price of $6.87 and is indicating a premium of 12.05% from its 52-week low price of $0.73. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.72 million shares which gives us an average trading volume of 4.80 million if we extend that period to 3-months.
Seres Therapeutics Inc (NASDAQ:MCRB) trade information
Upright in the green during last session for gaining 3.09%, in the last five days MCRB remained trading in the green while hitting it’s week-highest on Tuesday, 03/19/24 when the stock touched $0.83 price level, adding 2.8% to its value on the day. Seres Therapeutics Inc’s shares saw a change of -40.62% in year-to-date performance and have moved 7.07% in past 5-day. Seres Therapeutics Inc (NASDAQ:MCRB) showed a performance of -20.07% in past 30-days. Number of shares sold short was 16.1 million shares which calculate 4.96 days to cover the short interests.
Seres Therapeutics Inc (MCRB) estimates and forecasts
Statistics highlight that Seres Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -69.99% of value to its shares in past 6 months, showing an annual growth rate of -29.21% while that of industry is 12.50. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 40.40% in the current quarter and calculating -186.10% decrease in the next quarter. This year revenue growth is estimated to fall -98.90% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $250k for the same. And 6 analysts are in estimates of company making revenue of $250k in the next quarter that will end on Jun 2024. Company posted $1.38 million and $126.47 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -81.90% while estimating it to be -99.80% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 18.22% during past 5 years.
MCRB Dividends
Seres Therapeutics Inc is more likely to be releasing its next quarterly report between May 07 and May 13 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Seres Therapeutics Inc (NASDAQ:MCRB)’s Major holders
Insiders are in possession of 5.68% of company’s total shares while institution are holding 59.48 percent of that, with stock having share float percentage of 63.06%. Investors also watch the number of corporate investors in a company very closely, which is 59.48% institutions for Seres Therapeutics Inc that are currently holding shares of the company. Flagship Pioneering Inc. is the top institutional holder at MCRB for having 23.12 million shares of worth $110.73 million. And as of Jun 29, 2023, it was holding 18.03% of the company’s outstanding shares.
The second largest institutional holder is FMR, LLC, which was holding about 19.19 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 14.96% of outstanding shares, having a total worth of $91.9 million.
On the other hand, Federated Hermes Kaufmann Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Jul 30, 2023, the former fund manager was holding 11.07 million shares of worth $53.25 million or 8.63% of the total outstanding shares. The later fund manager was in possession of 6.52 million shares on Aug 30, 2023, making its stake of worth around $22.48 million in the company or a holder of 5.08% of company’s stock.
